Celebrex sales 2020

Celebrex, Pfizer's brand of celecoxib, is a mature oral nonsteroidal anti-inflammatory drug used primarily for osteoarthritis, rheumatoid arthritis, acute pain, and primary dysmenorrhea. Annual Sales of Celebrex reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Annual Sales of Celebrex, Celebra, 169590-42-5 reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Celecoxib drug usage statistics for the United States (2014 – 2024). Statistics include drug synonyms and therapeutic classes, including: Celecoxib, Celebrex, Elyxyb, Vyscoxa, Nonsteroidal Anti-inflammatory Drug. Pfizer's Neuroscience Drugs have seen revenues shrink from $6.4 billion in 2017 to $4.1 billion in 2019, and we expect these revenues to decline further in 2020 to around $2.3 billion … NORTH CHICAGO, Ill., Feb. 3, 2021 /PRNewswire/ — AbbVie (NYSE: ABBV) announced financial results for the fourth quarter and full year ended December 31, 2020. "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic," said Richard A. Gonzalez, chairman and chief executive … Historical largest selling pharmaceuticals 2020-2024 2024 The top ten best-selling pharmaceuticals of 2024. Sales in billion USD. [2] We have compiled a list of global top 20 blockbuster prescription drugs based on their sales in 2020. In the Top 20 list, the top position was maintained by AbbVie's leading drug Humira with $20.35 of total sales in 2020 The Top 20 Drugs and Vaccines by Worldwide Sales in 2020 Every year, shortly after the first quarter results, Fierce Pharma, with the assistance of Evaluate Pharma, issues the list of the Top 20 drugs by worldwide sales. What are Celebrex (celecoxib) sales, and who reports the numbers? Celebrex (celecoxib) is marketed by Pfizer and tracked in industry spending and sales reporting systems that compile prescription demand, revenue, and market share by country and time period. One of Pfizer's top-selling products is suddenly vulnerable to generic competition 18 months earlier than expected. A U.S. court nixed a key Celebrex patent, putting the pain drug up for a sales … Celecoxib Market size was valued at USD 1640.9 Million in 2023 & is projected to reach USD 2866.8 Million by 2031, growing at a CAGR of 8.8% from 2024-2031 The report provides key trends, growth drivers, segment analysis, and detailed forecast insights. Annual Sales of Celebrex, Celebra, Celecoxib reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Global Celebrex Capsules market reached USD 2.06 billion in 2025, driven by rising chronic pain and inflammatory disorder prevalence worldwide. Celecoxib Market size is projected to grow from 1.88 billion in 2026 to 3.98 billion by 2035, at a CAGR of 8.7% during the forecast period. Thanks to the team at EvaluatePharma and its Vantage 2020 Preview report, we here at FiercePharma have compiled a list of top 10 drugs by estimated sales increase in 2020–a group comprising … Drug Sales Expectation Change Core Adjustments Net Debt / EBITDA Ratios Dividend Yield Revenue High/Low Analysis Net Profit High/Low Analysis Receivables Outstanding Long-term Cumulative P&L Net vs Revenue CAGR Scatter EU Major US Major Japanese US Big Biotech * Upgrades / Downgrades Sector Performance Charts R&D Pipeline ANTICANCER – $218,005m … Drugs containing Celebrex that physicians and other health care providers prescribed in 2013 under the Medicare Part D Prescription Drug Program Pfizer Inc.'s Celebrex gained a majority of sales for new-generation painkillers in the month after Merck & Co. yanked Vioxx because of safety concerns, according to IMS Health, a pharmaceutical … US sales for celecoxib ['Celebrex'; Searle] passed the $US 1 billion mark at the beginning of October after less than one year on the market, reports Scrip. 1 The cyclo-oxygenase-2 (COX-2) inhibitor was launched in the US in January of this year. Celecoxib Capsule market valued at $1.95 billion in 2025, projected to reach $2.99 billion by 2034 at 4.8% CAGR. Comprehensive analysis of strength, application, and distribution channels. Annual pharmaceutical drug sales This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. Official website of CELEBREX® (celecoxib) Capsules. Read the Med Guide and Full Prescribing Information, including Boxed WARNING. Dominance of Generic Products: Following the patent expiration of the original brand (Celebrex), the market has seen a surge in generic celecoxib capsules. This trend has dramatically increased affordability and availability, making the treatment accessible to a wider population and driving overall volume sales. Focus on Combination Therapies: Pharmaceutical companies are exploring the … CELEBREX (celecoxib) is a selective COX-2 inhibitor approved for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea. Learn about Celebrex (celecoxib) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives. Celecoxib (Celebrex) is a moderately priced drug used to treat arthritis and ankylosing spondylitis. It may also be used for pain or painful monthly periods. This drug is slightly more popular than comparable drugs. It is available in brand and generic form. Generic celecoxib is covered by most Medicare and insurance plans, but some pharmacy coupons or cash prices may be lower. With the … Access 100,000+ Professional Market Research Reports with 18+ Years Expertise. Get Customized Industry Analysis, IPO Consulting & Business Plans. Trusted by 60,000+ Clients in 5 Languages. Otezla* generated $617 million of sales in the fourth quarter of 2020, and $2.2 billion for the full year. G.D. Searle & Co.'s blockbuster new arthritis drug, Celebrex, is shattering pharmaceutical industry records as the nation's most widely prescribed brand-name drug. Adding to its success, most … Celebrex is a Pfizer's blockbuster anti-inflammatory drug. Global sales of Celebrex exceeded USD2.1 billion, in the first nine months of 2013. Patent exclusivity for Celebrex in the U.S. expired in 2014. Multiple generic manufacturers entered the market between 2014 and 2020, triggering a drastic decrease in prices. Patent litigation and "Paragraph IV" challenges continue to influence the timing of generic entry in various jurisdictions. Price Trends and Projections Historical Pricing … Celecoxib (Celebrex) is a moderately priced drug used to treat arthritis and ankylosing spondylitis. It may also be used for pain or painful monthly periods. This drug is slightly more popular than comparable drugs. It is available in brand and generic form. Generic celecoxib is covered by most Medicare and insurance plans, but some pharmacy coupons or cash prices may be lower. With the … Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). [8] It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. [8] The Celebrex Capsules industry revenue is expected to be around $1.6 billion in 2026 and expected to showcase growth with 7.6% CAGR between 2026 and 2035. Building on this outlook, the celecoxib capsule market continues to hold strong clinical and commercial relevance due to its established efficacy in managing pain and inflammation associated with chronic conditions such as osteoarthritis and … RELATED: The top 20 drugs by global sales in 2019 As biosims and generics hit sales of several of the industry's top drugs, Remicade's 2020 performance shows that entrenched biologics can keep … Learn about CELEBREX® (celecoxib) Capsules and read the Med Guide and Full Prescribing Information, including Boxed WARNING. Celebrex (celecoxib) was Pfizer's fourth-biggest hit last year, with sales of $2.9 billion. Mylan is not happy that Teva will reap most of the generic sales of Celebrex out of the gate.